Recommended Suppliersmore
Description Feedback
Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.
Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.
Syndax pharmaceuticals currently holds the rights to Entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.

Properties Feedback
Density:1.315 g/cm3
Melting Point:159-160ºC
Boiling Point:566.7ºC at 760mmHg
Flash Point:296.6ºC
Refractive Index:1.672
Storage Condition:-20ºC
Vapor Pressure:7.31E-13mmHg at 25°C

Safety Info Feedback
Safety Statements:S26; S36
WGK Germany:3
Risk Statements:R36/37/38
Hazard Codes:Xi

MSDS
Coming Soon!


Synthesis Route Total: 8 Synthesis Route
 
1379471-51-8
~89%
209783-80-2
View Detail
 
95-54-5
241809-79-0
~82%
209783-80-2
View Detail

Precursor and Product